Blanket Purchase Agreement 36F79726D031E-36E79726A0012

Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, holds a multiple-award General Services Administration (GSA) Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs, awarded February 15, 2016, with an ultimate completion date of February 14, 2026, and a ceiling value of $719,535,960.00. The contract operates without set-aside designation due to the specialized and often single-source nature of the biopharmaceutical...

Takeda Pharmaceuticals America Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs National Acquisition Center for specialized pharmaceutical products valued at $131.0 million, effective July 15, 2025, through March 12, 2026. This child contract operates under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and covers nine therapeutic agents: CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, FIRAZYR,...

The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...

Daiichi Sankyo, Inc. (UEI: YUKQY5G72Q29) was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center on May 22, 2025, with a ceiling value of $80,206.95 and an ultimate completion date of May 21, 2026, with four optional one-year renewal periods. The BPA, established under the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), authorizes VA healthcare facilities within Veterans Integrated Service Networks 20...

Otsuka America Pharmaceutical Inc. was awarded a single-award Blanket Purchase Agreement (BPA) by the National Acquisition Center with a ceiling value of $15 million and an ultimate completion date of March 26, 2025. This BPA, established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), enables the Department of Veterans Affairs to procure Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. The...

This Blanket Purchase Agreement (BPA), awarded to Ionis Pharmaceuticals, Inc. on June 16, 2025, establishes a single-award indefinite delivery vehicle with a ceiling value of $4.26 million and an ultimate completion date of September 2, 2025. The agreement is funded through the National Acquisition Center, a civilian federal agency, and does not employ any set-asides. The BPA procures TryngolZA, a specialized pharmaceutical product, with this agreement replacing a prior BPA (36E79725A0020)....

This Blanket Purchase Agreement, awarded on October 4, 2024, to Takeda Pharmaceuticals America, Inc., establishes a single-award indefinite delivery vehicle valued at $123.5 million for the procurement of ICLUSIG (ponatinib), a specialized oncology pharmaceutical product. The contract is administered by the National Acquisition Center, a civilian federal agency, and will remain in effect through September 17, 2025. As a child contract under the parent General Services Administration Schedule for...

This Blanket Purchase Agreement, awarded on October 4, 2025, by the National Acquisition Center (a civilian federal agency) to Takeda Pharmaceuticals America, Inc., establishes a $43.8 million single-award indefinite delivery vehicle for the supply of ICLUSIG (ponatinib) to Department of Veterans Affairs medical facilities. The contract, which operates as a child contract under the General Services Administration Schedule for Pharmaceuticals and Drugs (FSS-61-IB), enables VA facilities to...

Day One Biopharmaceuticals, Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) by the National Acquisition Center for the supply of OJEMDA and related pharmaceutical products to federal healthcare agencies. The BPA, valued at $15.0 million with a completion date of March 7, 2027, was awarded on March 8, 2025, and represents Exercise Option Year 1 of the underlying indefinite delivery vehicle (BPA 36E79725A0007). The contract was issued without set-aside provisions,...

This Blanket Purchase Agreement, awarded on December 1, 2021, by the National Acquisition Center (a civilian federal agency) to EDW Pharma, Inc., establishes a single-award indefinite delivery vehicle for the procurement of Tiglutik with a ceiling value of $848,847.60. The contract operates under the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is scheduled for ultimate completion on November 30, 2026. No set-aside provisions were applied to...